Decision support. ChironAI drafts the SOAP note from the consultation context. The clinician edits, attests, and signs every note before it enters the chart. ChironAI does not make a regulatory clearance claim; see Disclosures.

ChironAI CDSDocumentation

Every statement in the note traces to its source.

ChironAI generates SOAP notes that physicians can sign. The structural innovation: every statement in the assessment links to its underlying source field, source value, and source date in the chart. Click a statement; see the chart row that produced it. Twelve locales. Versioned. Cryptographically signed.

Source-grounded SOAP note

What a chart-ready note looks like.

ChironAI™ CDSSOAP note \u00b7 follow-up visit \u00b7 T2DM

Must review before final

Decision-support output. Clinician review and attestation required before this content is signed into the chart.

Subjective

58-year-old female with type 2 diabetes returns for routine follow-up. Reports adherence to metformin 1000 mg BID. Self-monitored fasting glucoses 140–180 mg/dL. No hypoglycemic episodes. No polyuria, no visual changes. Diet adherence intermittent; exercise sporadic.

Objective

BP 138/86, HR 78, BMI 32.4. Heart and lung exam unremarkable. Diabetic foot exam: protective sensation intact bilaterally; no ulcers.

Assessment

A1c 7.8% — above target (< 7.0% for this patient profile per ADA Standards of Care 2026). (source: Lab: HbA1c 7.8%, 2026-04-22)

Source — Lab. HbA1c 7.8% 2026-04-22

eGFR 78 mL/min/1.73m² with no microalbuminuria — stable kidney function, supportive of intensified glucose-lowering therapy. (source: Lab: eGFR 78 / UACR < 30, 2026-04-22)

Source — Lab. eGFR 78 / UACR < 30 2026-04-22

Blood pressure above ADA 2026 target (<130/80) for this patient with diabetes — hypertension management warrants intensification. (source: Vitals: 138/86 mmHg, 2026-05-12)

Source — Vitals. 138/86 mmHg 2026-05-12

Plan

  1. 1.Add empagliflozin 10 mg daily (SGLT2-i preferred per ADA 2026 for T2DM with elevated BP and adequate eGFR).
  2. 2.Increase lisinopril from 10 mg to 20 mg daily for BP control.
  3. 3.Re-check A1c, BMP, UACR in 3 months.
  4. 4.Nutrition counseling referral; patient agrees.
  5. 5.Diabetic eye exam due (last 14 months ago).
Illustrative — representative of product UI. Synthetic case data; not from any real patient.
Twelve locales, ship-ready

The same SOAP note, in the patient’s language.

English

en left-to-right

Español

es left-to-right

Français

fr left-to-right

Deutsch

de left-to-right

Português

pt left-to-right

Pусский

ru left-to-right

العربية

ar right-to-left

हिन्दी

hi left-to-right

中文

zh left-to-right

한국어

ko left-to-right

Tagalog

tl left-to-right

Tiếng Việt

vi left-to-right

Multi-language output is not translation of an English note after the fact. The note is composed natively in the target locale, with the same source-grounding contract preserved.

Versioning + signatures

Immutable history. Verifiable integrity.

Every signed document gets a SHA-256 hash of its content at signature time, captured alongside the signing clinician’s identity and timestamp. Any subsequent modification of the content fails hash verification.

Amendments to signed documents are recorded as new versions; the original signed version stays verifiable end to end. The audit chain stamps each version, so forensic reconstruction is always possible.

Bulk-sign workflow accelerates the close of day. Each document still requires the physician’s individual attestation; bulk-sign is a UI optimization, not a compliance shortcut.

A note to the reader

See how the documentation posture composes with the rest of the consultation.

See how it works →See the full capabilities inventory